217 related articles for article (PubMed ID: 3711262)
1. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine.
Montini M; Pagani G; Gianola D; Pagani MD; Salmoiraghi M; Ferrari L; Lancranjan I
J Clin Endocrinol Metab; 1986 Jul; 63(1):266-8. PubMed ID: 3711262
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N
Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
[TBL] [Abstract][Full Text] [Related]
3. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR).
Schettini G; Lombardi G; Merola B; Colao A; Miletto P; Caruso E; Lancranjan I
Clin Endocrinol (Oxf); 1990 Aug; 33(2):161-9. PubMed ID: 2225475
[TBL] [Abstract][Full Text] [Related]
4. A long-acting repeatable form of bromocriptine as long-term treatment of prolactin-secreting macroadenomas: a multicenter study.
Brue T; Lancranjan I; Louvet JP; Dewailly D; Roger P; Jaquet P
Fertil Steril; 1992 Jan; 57(1):74-80. PubMed ID: 1730334
[TBL] [Abstract][Full Text] [Related]
5. Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine.
Ciccarelli E; Miola C; Grottoli S; Avataneo T; Lancranjan I; Camanni F
J Clin Endocrinol Metab; 1993 Feb; 76(2):484-8. PubMed ID: 8432794
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of a single injectable dose of bromocriptine long acting in the treatment of macroprolactinomas.
Schettini G; Lombardi G; Merola B; Miletto P; Fariello C; Cirillo S; Fusco R; Lancranjan I
J Endocrinol Invest; 1988 Jan; 11(1):47-51. PubMed ID: 3361075
[TBL] [Abstract][Full Text] [Related]
7. Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years.
Haase R; Jaspers C; Schulte HM; Lancranja I; Pfingsten H; Orri-Fend M; Reinwein D; Benker G
Clin Endocrinol (Oxf); 1993 Feb; 38(2):165-76. PubMed ID: 8435897
[TBL] [Abstract][Full Text] [Related]
8. Parlodel LAR in the treatment of macroprolactinomas.
Kocijancic A; Prezelj J; Vrhovec I; Lancranjan I
Acta Endocrinol (Copenh); 1990 Feb; 122(2):272-6. PubMed ID: 2316314
[TBL] [Abstract][Full Text] [Related]
9. [Short-term effect of delayed-action injectable bromocriptine in macroprolactinoma. French multicenter study].
Brue T; James-Deidier A; Louvet JP; Dewailly D; Roger P; Schlienger JL; Schaison G; Hartemann P; Jaquet P
Ann Endocrinol (Paris); 1991; 52(4):273-82. PubMed ID: 1818531
[TBL] [Abstract][Full Text] [Related]
10. Effects of a new long-acting form of bromocriptine on tumorous hyperprolactinemia.
Ciccarelli E; Ghigo E; Mazza E; Andreis M; Massara F; Lancranjan I; Camanni F
J Endocrinol Invest; 1987 Apr; 10(2):179-82. PubMed ID: 3584856
[TBL] [Abstract][Full Text] [Related]
11. Long-acting bromocriptine for the acute treatment of large macroprolactinomas.
Zarate A; Moran C; Miranda R; Loyo M; Medina M; Fonseca ME
J Endocrinol Invest; 1987 Jun; 10(3):233-6. PubMed ID: 3624799
[TBL] [Abstract][Full Text] [Related]
12. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study.
Molitch ME; Elton RL; Blackwell RE; Caldwell B; Chang RJ; Jaffe R; Joplin G; Robbins RJ; Tyson J; Thorner MO
J Clin Endocrinol Metab; 1985 Apr; 60(4):698-705. PubMed ID: 3882737
[TBL] [Abstract][Full Text] [Related]
13. Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases.
Beckers A; Petrossians P; Abs R; Flandroy P; Stadnik T; de Longueville M; Lancranjan I; Stevenaert A
J Clin Endocrinol Metab; 1992 Jul; 75(1):275-80. PubMed ID: 1619019
[TBL] [Abstract][Full Text] [Related]
14. [Long-acting and repeatable dose bromocriptine in the prolonged treatment of prolactinoma].
Pereira JL; García-Luna PP; Leal-Cerro A; Cortés A; Trujillo F; Villamil F; Vaquero F; Revuelta M; Astorga R
Med Clin (Barc); 1994 Jun; 103(2):59-64. PubMed ID: 8051973
[TBL] [Abstract][Full Text] [Related]
15. Long-acting injectable bromocriptine (Parlodel LAR) in the chronic treatment of prolactin-secreting macroadenomas.
Lengyel AM; Mussio W; Imamura P; Vieira JG; Lancranjan I
Fertil Steril; 1993 May; 59(5):980-7. PubMed ID: 8486199
[TBL] [Abstract][Full Text] [Related]
16. Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal.
Moriondo P; Travaglini P; Nissim M; Conti A; Faglia G
J Clin Endocrinol Metab; 1985 Apr; 60(4):764-72. PubMed ID: 3919052
[TBL] [Abstract][Full Text] [Related]
17. Short-term management of macroprolactinomas with a new injectable form of bromocriptine.
Bronstein MD; Cardim CS; Marino R
Surg Neurol; 1987 Jul; 28(1):31-7. PubMed ID: 3589939
[TBL] [Abstract][Full Text] [Related]
18. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
19. Reenlargement of macroprolactinomas during bromocriptine treatment: report of two cases.
Dallabonzana D; Spelta B; Oppizzi G; Tonon C; Luccarelli G; Chiodini PG; Liuzzi A
J Endocrinol Invest; 1983 Feb; 6(1):47-50. PubMed ID: 6841916
[TBL] [Abstract][Full Text] [Related]
20. Treatment with long acting repeatable bromocriptine (Parlodel-LAR*) in patients with macroprolactinomas: long-term study in 29 patients.
Jamrozik SI; Bennet AP; James-Deidier A; Tremollieres F; Saint-Martin F; Dumoulin S; Valat-Coustols M; de Glisezinski I; Tremoulet M; Manelfe C; Louvet JP
J Endocrinol Invest; 1996; 19(7):472-9. PubMed ID: 8884542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
